Mouse Anti-MUC1 Recombinant Antibody (clone AR20.5) (CAT#: PABC-399)

Figure 1 Interferon (IFN)-γ enzyme-linked immunospot (ELISPOT) data from patients treated with BrevaRex mAb-AR20.5.

T-cell responses to MUC1 pre- and post-mAb-AR20.5 treatment were assessed for production of IEN-γ by ELISPOT assay in response to stimulation with 31mer MUCI peptide. PBMC obtained from heparinized blood of patients before and after administration of mAb-AR20.5 were isolated on Ficoll-Hypaque gradients and cryopreserved. Cells from pre- and post therapy samples were thawed, washed and stimulated with the 31mer MUCI peptide for 1 week, using autologous PBMC as antigen presenting cells. Cultures were then restimulated for 24 h with MUC1 peptide-pulsed autologous dendritic cells generated in parallel with the stimulated PBMC cultures. MUC1-specific T cells were quantified in an IFN-γ ELISPOT.

De Bono, J. S., Rha, S., Stephenson, J., Schultes, B. C., Monroe, P., Eckhardt, G. S., ... & Rowinsky, E. K. (2004). Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity. Annals of oncology, 15(12), 1825-1833.

Figure 2 Antitumor effect of MAb AR20.5 in CB6F1 mice.

CB6Fl mice were immunized four times with MAb AR20.5 or controls (three times prior to tumor inoculation (Days 0.7. and 14), once post-tumor inoculation (Day 28) with 50 ug/mouse, i.v.). Tumors were induced by iniection of 413BCR cells into the tail vein (Day 21). The mice were observe for distress and weight loss and sacrificed when they became moribund. Survival times are plotted for each group (n= 5) and p values calculated by log-rank test.

Qi, W., Schultes, B. C., Liu, D., Kuzma, M., Decker, W., & Madiyalakan, R. (2001). Characterization of an anti-MUC1 monoclonal antibody with potential as a cancer vaccine. Hybridoma and hybridomics, 20(5-6), 313-324.

Figure 3 CDC and ADCC properties of MAb AR20.5.

ZR75-1 cells were labeled with ⁵¹Cr and incubated with MAb AR20.5 or MAb AR20.5 (IgM) or control IgG, (mouse IgG1, MOPC-21) in a range of 0.625 to 20 ug/mL for 1 h at room temperature. Cells were washed once and then incubated with either 15% fresh human serum in complete RPMI 1640 media for 4 h for CDC (A) or with human PBMC in an effector: target ratio of 50:1 for ADCC (B). Supernatants were harvested and tested for ⁵¹Cr release. Specific lysis was calculated by subtracting the spontaneous release from each sample and dividing the results by the corrected makimum release by ZR75-1 cells in the presence of Triton X-100. Mouse IgG1 was used as negative control.

Qi, W., Schultes, B. C., Liu, D., Kuzma, M., Decker, W., & Madiyalakan, R. (2001). Characterization of an anti-MUC1 monoclonal antibody with potential as a cancer vaccine. Hybridoma and hybridomics, 20(5-6), 313-324.